Vonoprazan and amoxicillin dual therapy as the first‐line treatment of Helicobacter pylori infection: A systematic review and meta‐analysis

医学 阿莫西林 内科学 幽门螺杆菌 不利影响 科克伦图书馆 荟萃分析 胃肠病学 随机对照试验 抗生素 微生物学 生物
作者
Ren‐Chun Du,Yuxin Hu,Yaobin Ouyang,Li‐Xiang Ling,Jing‐Yuan Xu,Rina Sa,Xiao‐Shun Liu,Junbo Hong,Yin Zhu,Nonghua Lü,Yi Hu
出处
期刊:Helicobacter [Wiley]
卷期号:29 (1) 被引量:23
标识
DOI:10.1111/hel.13039
摘要

Abstract Background Recent clinical trials have evaluated the efficacy of vonoprazan‐amoxicillin (VA) dual therapy as the first‐line treatment for Helicobacter pylori infection in different regions with inconsistent results reported. In this systematic review and meta‐analysis, we aimed to evaluate the efficacy of VA dual therapy compared to the currently recommended therapy for eradicating H. pylori . Materials and Methods A comprehensive search of the PubMed, Cochrane, and Embase databases was performed using the following search terms: (“ Helicobacter ” OR “ H. pylori ” OR “ Hp ”) AND (“vonoprazan” OR “potassium‐competitive acid blocker” OR “P‐CAB”) AND (“amoxicillin” OR “penicillin”) AND (“dual”). The primary outcome was to evaluate the eradication rate according to intention‐to‐treat and per‐protocol analysis. The secondary outcomes were adverse events and compliance. Results A total of 15 studies involving 4, 568 patients were included. The pooled eradication rate of VA dual therapy was 85.0% and 90.0% by intention‐to‐treat and per‐protocol analysis, respectively. The adverse events rate and compliance of VA dual therapy were 17.5% and 96%, respectively. The efficacy of VA dual therapy was superior to proton pump inhibitors‐based triple therapy (82.0% vs. 71.4%, p < 0.01) but lower than vonoprazan‐containing quadruple therapy (83.1% vs. 93.3%, p = 0.02). 7‐day VA dual therapy showed lower eradication rates than 10‐day (χ 2 = 24.09, p < 0.01) and 14‐day VA dual therapy (χ 2 = 11.87, p < 0.01). The adverse events rate of VA dual therapy was lower than vonoprazan triple therapy (24.6% vs. 30.9%, p = 0.01) and bismuth‐containing quadruple therapy (20.5% vs. 47.9%, p < 0.01). No significant difference of compliance was observed between VA dual therapy and each subgroup. Conclusion VA dual therapy, a novel regimen, showed high efficacy as the first‐line treatment for H. pylori eradication, which should be optimized before application in different regions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
一天完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
1秒前
GHOMON完成签到,获得积分10
2秒前
2秒前
语亦菲扬921完成签到,获得积分10
2秒前
丘比特应助liguanyu1078采纳,获得10
2秒前
janie发布了新的文献求助10
2秒前
byzhao19发布了新的文献求助10
2秒前
JamesPei应助大神装采纳,获得10
2秒前
水木应助hsialy采纳,获得10
2秒前
JY完成签到,获得积分20
3秒前
4秒前
顺利山柏完成签到 ,获得积分10
4秒前
4秒前
5秒前
5秒前
bing发布了新的文献求助10
5秒前
BenQiu发布了新的文献求助10
5秒前
半柚应助纯情的亦竹采纳,获得10
5秒前
txg发布了新的文献求助10
6秒前
yio关闭了yio文献求助
7秒前
zimablue发布了新的文献求助10
7秒前
7秒前
福尔摩云发布了新的文献求助30
7秒前
niunai完成签到 ,获得积分10
8秒前
JY发布了新的文献求助10
8秒前
mmddlj完成签到 ,获得积分10
8秒前
byzhao19完成签到,获得积分10
9秒前
ting发布了新的文献求助10
10秒前
whatever应助能干的吐司采纳,获得10
10秒前
11秒前
思源应助w2503采纳,获得10
11秒前
霸气皮皮虾完成签到,获得积分20
11秒前
FashionBoy应助Young采纳,获得10
11秒前
12秒前
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970949
求助须知:如何正确求助?哪些是违规求助? 3515634
关于积分的说明 11179061
捐赠科研通 3250769
什么是DOI,文献DOI怎么找? 1795474
邀请新用户注册赠送积分活动 875831
科研通“疑难数据库(出版商)”最低求助积分说明 805188